Oxford Biomedica

Rising Capital Costs And Fierce Competition Will Constrain CDMO Growth

AnalystLowTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

31 Aug 25

AnalystLowTarget's Fair Value

UK£3.80

51.3% overvalued

04 Sep

UK£5.75

74.8%

3.2%

74.8%

3.2%

Edit anytime before Aug 31 10:37 PM. Then post Updates to your followers.

Author's Valuation

UK£3.8

51.3% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

UK£3.8

51.3% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.94%

Biotech revenue growth rate

7.48%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.95%

Calculation

UK£14.68m

Earnings '28

33.57x

PE Ratio '28

UK£492.78m

Market Cap '28

UK£492.78m

Market Cap '28

105.96m

No. shares '28

UK£4.65

Share Price '28

UK£4.65 Share Price '28

Discounted to 2025 @ 6.96% p.a.

UK£3.80

Fair Value '25